ENLIVEX THERAPEUTICS LTD (ENLV) Stock Price, Quote, News and Overview
NASDAQ:ENLV - Nasdaq - IL0011319527 - Common Stock - Currency: USD
ENLV Quote, Performance and Key Statistics
NASDAQ:ENLV (4/23/2025, 10:22:17 AM)
0.92
+0.03 (+3.37%)
The current stock price of ENLV is 0.92 USD. In the past month the price decreased by -12.75%. In the past year, price decreased by -38.19%.
ENLV Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.51 | 313.39B | ||
| AMGN | AMGEN INC | 14.23 | 151.60B | ||
| GILD | GILEAD SCIENCES INC | 23.07 | 132.60B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1712.31 | 127.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.16 | 65.65B | ||
| ARGX | ARGENX SE - ADR | 323.77 | 36.77B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.96B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.68B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.48B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 23.69B | ||
| NTRA | NATERA INC | N/A | 20.60B | ||
| BIIB | BIOGEN INC | 7.31 | 17.61B |
Related stock screener links
About ENLV
Company Profile
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Company Info
ENLIVEX THERAPEUTICS LTD
14 Einstein St.
Ness Ziona 7403618 IL
CEO: Oren Hershkovitz
Employees: 71
Company Website: https://www.enlivex.com/
Investor Relations: https://enlivex.com/investor-relations/
Phone: 97286623301
ENLIVEX THERAPEUTICS LTD / ENLV FAQ
What is the stock price of ENLIVEX THERAPEUTICS LTD today?
The current stock price of ENLV is 0.92 USD. The price increased by 3.37% in the last trading session.
What is the ticker symbol for ENLIVEX THERAPEUTICS LTD stock?
The exchange symbol of ENLIVEX THERAPEUTICS LTD is ENLV and it is listed on the Nasdaq exchange.
On which exchange is ENLV stock listed?
ENLV stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ENLIVEX THERAPEUTICS LTD stock?
8 analysts have analysed ENLV and the average price target is 10.2 USD. This implies a price increase of 1008.7% is expected in the next year compared to the current price of 0.92. Check the ENLIVEX THERAPEUTICS LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ENLIVEX THERAPEUTICS LTD worth?
ENLIVEX THERAPEUTICS LTD (ENLV) has a market capitalization of 20.23M USD. This makes ENLV a Nano Cap stock.
How many employees does ENLIVEX THERAPEUTICS LTD have?
ENLIVEX THERAPEUTICS LTD (ENLV) currently has 71 employees.
What are the support and resistance levels for ENLIVEX THERAPEUTICS LTD (ENLV) stock?
ENLIVEX THERAPEUTICS LTD (ENLV) has a support level at 0.89 and a resistance level at 0.89. Check the full technical report for a detailed analysis of ENLV support and resistance levels.
Should I buy ENLIVEX THERAPEUTICS LTD (ENLV) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ENLV, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ENLV, evaluating the profitability, health, valuation and growth aspects
- ENLIVEX THERAPEUTICS LTD (ENLV) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ENLIVEX THERAPEUTICS LTD (ENLV) Sales and EPS estimates to see what analysts future expectations are.
- ENLIVEX THERAPEUTICS LTD (ENLV) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ENLIVEX THERAPEUTICS LTD (ENLV) Insider and Institutional Ownership to learn about the owners and their transactions.
- ENLIVEX THERAPEUTICS LTD (ENLV) Stock Chart to make your own analysis
- ENLIVEX THERAPEUTICS LTD (ENLV) Latest news and press-releases to stay up to date.
Does ENLIVEX THERAPEUTICS LTD (ENLV) stock pay dividends?
ENLV does not pay a dividend.
What is the Price/Earnings (PE) ratio of ENLIVEX THERAPEUTICS LTD (ENLV)?
ENLIVEX THERAPEUTICS LTD (ENLV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.73).
What is the Short Interest ratio of ENLIVEX THERAPEUTICS LTD (ENLV) stock?
The outstanding short interest for ENLIVEX THERAPEUTICS LTD (ENLV) is 0.59% of its float. Check the ownership tab for more information on the ENLV short interest.
ENLV Technical Analysis
ENLV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ENLV. ENLV has a great financial health rating, but its profitability evaluates not so good.
ENLV Financial Highlights
Over the last trailing twelve months ENLV reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 53.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.54% | ||
| ROE | -71.21% | ||
| Debt/Equity | 0 |
ENLV Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ENLV. The Buy consensus is the average rating of analysts ratings from 8 analysts.